Active Research Protocols
- 02-I-0286 – A Pilot Study of the Safety and Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients with the Myeloproliferative Variant Hypereosinophilic Syndrome (HES) or Non-Myeloproliferative HES Refractory to Standard Therapy
- 12-I-0026 – Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014